Drug Trial Radar · NCT04282954
Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease
Last checked: Nov 19, 2026Latest source record: Jul 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
188
Actual
Start
Nov 15, 2019
Primary completion
Oct 20, 2020
Study completion Dec 11, 2020
Sponsor
- Lead sponsor
- Onconic Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 25, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clinical trial to evaluate the safety and efficacy of JP-1366 in patients with erosive gastroesophageal reflux disease
Conditions
- GERD
Interventions
JP-1366Drug
JP-1366, QD
JP-1366 placeboDrug
JP-1366 placebo, QD
Esomeprazole 40mgDrug
Esomeprazole 40mg, QD
Esomeprazole placeboDrug
Esomeprazole placebo, QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Accumulated mucosal defect cure rate*(%) at Week 8 following study drug administration (%)Time frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Severance Hospital and 19 hospitals
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.